Quetiapine in nine youths with autistic disorder

Robert L Findling, Nora K. McNamara, Barbara L. Gracious, Mary Ann O'Riordan, Michael D. Reed, Christine Demeter, Jeffrey L. Blumer

Research output: Contribution to journalArticle

Abstract

Objective: The aim of this study was to examine the effectiveness of quetiapine in adolescents suffering from autistic disorder (AD). Methods: This was a 12-week, open-label study, for which medically healthy patients with AD between the ages of 10 and 17 years were eligible. Quetiapine treatment was gradually increased over the first 6 weeks of the study, to a total daily dose of 300 mg/day. Doses could then be increased to a maximum daily dose of 750 mg/day. Outcome measures included the Children's Psychiatric Rating Scale (CPRS) and the Clinical Global Impressions (CGI) scale. Results: Nine (9) males were enrolled. Six (6) patients had previously been treated with other psychotropic agents. Although improvements in several symptom domains were observed on quetiapine, only 2 patients met a priori criteria for response ("much" or "very much improved" on the Clinical Global Impressions- Improvement Scale). In addition, only these same 2 patients' parents/guardians chose to continue quetiapine pharmacotherapy after study participation. Conclusions: These data suggest that quetiapine may not be a particularly effective agent in the treatment of adolescent patients with AD. However, should future studies be performed, it seems reasonable that they be conducted with more rigor, less treatment-resistant cohorts, and, possibly, a different dosing strategy.

Original languageEnglish (US)
Pages (from-to)287-294
Number of pages8
JournalJournal of Child and Adolescent Psychopharmacology
Volume14
Issue number2
DOIs
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Autistic Disorder
Child Psychiatry
Therapeutics
Parents
Outcome Assessment (Health Care)
Quetiapine Fumarate
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Findling, R. L., McNamara, N. K., Gracious, B. L., O'Riordan, M. A., Reed, M. D., Demeter, C., & Blumer, J. L. (2004). Quetiapine in nine youths with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 14(2), 287-294. https://doi.org/10.1089/1044546041649129

Quetiapine in nine youths with autistic disorder. / Findling, Robert L; McNamara, Nora K.; Gracious, Barbara L.; O'Riordan, Mary Ann; Reed, Michael D.; Demeter, Christine; Blumer, Jeffrey L.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 14, No. 2, 06.2004, p. 287-294.

Research output: Contribution to journalArticle

Findling, RL, McNamara, NK, Gracious, BL, O'Riordan, MA, Reed, MD, Demeter, C & Blumer, JL 2004, 'Quetiapine in nine youths with autistic disorder', Journal of Child and Adolescent Psychopharmacology, vol. 14, no. 2, pp. 287-294. https://doi.org/10.1089/1044546041649129
Findling, Robert L ; McNamara, Nora K. ; Gracious, Barbara L. ; O'Riordan, Mary Ann ; Reed, Michael D. ; Demeter, Christine ; Blumer, Jeffrey L. / Quetiapine in nine youths with autistic disorder. In: Journal of Child and Adolescent Psychopharmacology. 2004 ; Vol. 14, No. 2. pp. 287-294.
@article{c606242cbe104bd4a5a645e57bb7d45c,
title = "Quetiapine in nine youths with autistic disorder",
abstract = "Objective: The aim of this study was to examine the effectiveness of quetiapine in adolescents suffering from autistic disorder (AD). Methods: This was a 12-week, open-label study, for which medically healthy patients with AD between the ages of 10 and 17 years were eligible. Quetiapine treatment was gradually increased over the first 6 weeks of the study, to a total daily dose of 300 mg/day. Doses could then be increased to a maximum daily dose of 750 mg/day. Outcome measures included the Children's Psychiatric Rating Scale (CPRS) and the Clinical Global Impressions (CGI) scale. Results: Nine (9) males were enrolled. Six (6) patients had previously been treated with other psychotropic agents. Although improvements in several symptom domains were observed on quetiapine, only 2 patients met a priori criteria for response ({"}much{"} or {"}very much improved{"} on the Clinical Global Impressions- Improvement Scale). In addition, only these same 2 patients' parents/guardians chose to continue quetiapine pharmacotherapy after study participation. Conclusions: These data suggest that quetiapine may not be a particularly effective agent in the treatment of adolescent patients with AD. However, should future studies be performed, it seems reasonable that they be conducted with more rigor, less treatment-resistant cohorts, and, possibly, a different dosing strategy.",
author = "Findling, {Robert L} and McNamara, {Nora K.} and Gracious, {Barbara L.} and O'Riordan, {Mary Ann} and Reed, {Michael D.} and Christine Demeter and Blumer, {Jeffrey L.}",
year = "2004",
month = "6",
doi = "10.1089/1044546041649129",
language = "English (US)",
volume = "14",
pages = "287--294",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Quetiapine in nine youths with autistic disorder

AU - Findling, Robert L

AU - McNamara, Nora K.

AU - Gracious, Barbara L.

AU - O'Riordan, Mary Ann

AU - Reed, Michael D.

AU - Demeter, Christine

AU - Blumer, Jeffrey L.

PY - 2004/6

Y1 - 2004/6

N2 - Objective: The aim of this study was to examine the effectiveness of quetiapine in adolescents suffering from autistic disorder (AD). Methods: This was a 12-week, open-label study, for which medically healthy patients with AD between the ages of 10 and 17 years were eligible. Quetiapine treatment was gradually increased over the first 6 weeks of the study, to a total daily dose of 300 mg/day. Doses could then be increased to a maximum daily dose of 750 mg/day. Outcome measures included the Children's Psychiatric Rating Scale (CPRS) and the Clinical Global Impressions (CGI) scale. Results: Nine (9) males were enrolled. Six (6) patients had previously been treated with other psychotropic agents. Although improvements in several symptom domains were observed on quetiapine, only 2 patients met a priori criteria for response ("much" or "very much improved" on the Clinical Global Impressions- Improvement Scale). In addition, only these same 2 patients' parents/guardians chose to continue quetiapine pharmacotherapy after study participation. Conclusions: These data suggest that quetiapine may not be a particularly effective agent in the treatment of adolescent patients with AD. However, should future studies be performed, it seems reasonable that they be conducted with more rigor, less treatment-resistant cohorts, and, possibly, a different dosing strategy.

AB - Objective: The aim of this study was to examine the effectiveness of quetiapine in adolescents suffering from autistic disorder (AD). Methods: This was a 12-week, open-label study, for which medically healthy patients with AD between the ages of 10 and 17 years were eligible. Quetiapine treatment was gradually increased over the first 6 weeks of the study, to a total daily dose of 300 mg/day. Doses could then be increased to a maximum daily dose of 750 mg/day. Outcome measures included the Children's Psychiatric Rating Scale (CPRS) and the Clinical Global Impressions (CGI) scale. Results: Nine (9) males were enrolled. Six (6) patients had previously been treated with other psychotropic agents. Although improvements in several symptom domains were observed on quetiapine, only 2 patients met a priori criteria for response ("much" or "very much improved" on the Clinical Global Impressions- Improvement Scale). In addition, only these same 2 patients' parents/guardians chose to continue quetiapine pharmacotherapy after study participation. Conclusions: These data suggest that quetiapine may not be a particularly effective agent in the treatment of adolescent patients with AD. However, should future studies be performed, it seems reasonable that they be conducted with more rigor, less treatment-resistant cohorts, and, possibly, a different dosing strategy.

UR - http://www.scopus.com/inward/record.url?scp=3342943157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3342943157&partnerID=8YFLogxK

U2 - 10.1089/1044546041649129

DO - 10.1089/1044546041649129

M3 - Article

C2 - 15319025

AN - SCOPUS:3342943157

VL - 14

SP - 287

EP - 294

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 2

ER -